Statement: Patients in the primary trial receive 50mg/m2, 75mg/m2 and 80mg/m2 daily every 5 days for each 4-week cycle
Primary_evidence: INTERVENTION 1:    Phase 1   Azacitidine (Vidaza): 50mg/m2, 75mg/m2 or 100mg/m2 daily for 5 days for each 4-week cycle   Nab-paclitaxel (Abraxane): 100mg/m2 weekly for 3 weeks of each 4-week cycle